期刊文献+

自体造血干细胞移植治疗复发难治性外周T细胞淋巴瘤疗效及预后分析 被引量:4

Efficacy and prognosis of autologous hematopoietic stem cell transplantation in treating recurrent refractory peripheral T cell lymphoma
原文传递
导出
摘要 目的探讨自体造血干细胞移植治疗复发难治性外周T细胞淋巴瘤的临床疗效及预后因素。方法选择2010年1月—2016年1月宁波市鄞州人民医院接收的复发难治性外周T细胞淋巴瘤患者64例,均采用自体造血干细胞移植进行治疗,分析治疗效果、临床特征,采用COX回归进行预后分析。结果64例患者在自体干细胞移植后15 d内造血重建,采集中位外周单个核细胞为8.74×10^8/kg(6.34×10^8-16.72×10^8/kg),中位CD34^+细胞数为5.64×10^6/kg(3.43×10^6-9.62×10^6/kg)。中性粒细胞植入(>0.5×10^9/L)中位时间12 d(7-17 d),血小板植入(恢复20×10^9/L)中位时间13 d(7-19 d)。随访中位时间26个月(8-48个月),截止到随访结束,死亡28例,其中24例为复发患者,4例移植相关并发症死亡,死亡率为43.75%,生存率为56.25%。28例(43.75%)患者移植后达CR,21例(32.81%)患者为PR,14例(21.88%)为SD。3年总生存率为59.38%,3年无进展生存率为48.44%,最长无病生存时间达41个月。多因素COX回归分析显示,骨髓累及、PIT评分、移植后是否获得CR是不良预后的独立影响因素。结论自体造血干细胞移植对复发难治性外周T细胞淋巴瘤效果显著,骨髓累及、PIT评分、移植后是否获得CR是不良预后的影响因素。 Objective To investigate the clinical effect and prognostic factors of autologous hematopoietic stem cells transplantation(AHSCT)in the treatment of recurrent refractory peripheral T cell lymphoma.Methods Sixty-four cases of recurrent refractory peripheral T cell lymphoma admitted in Yinzhou people’s Hospital between January 2010 and January 2016 received AHSCT treatment.The patients were followed up for the analysis of therapeutic effect and clinical characteristics,and the prognosis was analyzed by COX regression.Results Hematopoietic reconstitution in 64 patients within 15 days after AHSCT was observed.The median peripheral mononuclear cells were 8.74×10^8/kg(6.34×10^8-16.72×10^8/kg),the median CD34 cell count was 5.64×10^6/kg(3.43×10^6-9.62×10^6/kg).The median time of neutrophil implantation(>0.5×10^9/L)was 12 d(7-17 d),the median time of platelet implantation(20×10^9/L)was 13 d(7-19 d).The median time of follow-up was 26 months(8-48 months).By the end of the follow-up period,28 cases of them died,the death rate was 43.75%(survival rate 56.25%);24 cases died of recurrence and 4 cases died of transplantation related complications.Response rates:complete response(CR)43.75%(28/64),partial response(PR)32.81%(21/64),stable disease(SD)21.88%(14/64).The 3-years overall survival was 59.38%.Three-year progression-free survival rate was 48.44%,the longest disease-free survival time was 41 months.Multivariate COX regression analysis showed that bone marrow involvement,the Prognostic Index for T-cell lymphoma(PIT)and complete response after AHSCT were independent factors of poor prognosis.Conclusion AHSCT has a significant effect on recurrent refractory peripheral T cell lymphoma.The bone marrow involvement,PIT score and CR after the transplantation will give a bad prognosis.
作者 陈冬 裴仁治 陆滢 曹俊杰 陈列光 刘旭辉 张丕胜 刘辉 CHEN Dong;PEI Ren-zhi;LU Ying;CAO Jun-jie;CHEN Lie-guang;LIU Xu-hui;ZHANG PI-sheng;LIU Hui(Department of Hematology,the People's Hospital of Yinzhou,Ningbo,Zhejiang 315040,China;不详)
出处 《中华全科医学》 2020年第1期59-61,157,共4页 Chinese Journal of General Practice
基金 浙江省自然科学基金(LY18H160008).
关键词 淋巴瘤 自体造血干细胞移植 回归分析 随访研究 Lymphoma Autologous hematopoietic stem cells transplantation Regression analysis Follow-Up studies
作者简介 通信作者:陈冬,E-mail:chendong0218@163.com
  • 相关文献

参考文献7

二级参考文献79

  • 1郭智,谭晓华,高锦,楼金星,刘晓东,何学鹏.CIK治疗耐药性非霍奇金淋巴瘤疗效观察[J].实用癌症杂志,2006,21(1):15-16. 被引量:29
  • 2袁晓莉,李桥川,邹德慧,赵耀中,王亚非,王迎,张静薇,邱录贵.54例高危侵袭性T细胞非霍奇金淋巴瘤的回顾性分析[J].中华血液学杂志,2007,28(7):454-457. 被引量:7
  • 3Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
  • 4O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 ;29(9): 1182-1189.
  • 5Corradini P, Tarella C, Zallio F, et al. Long-term follow-upof patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9): 1533-1538.
  • 6Rodriguez J, Conde E, Gutirrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The GeI-Tamo Study Group. Eur J Haematol. 2007;79(1):32-38.
  • 7Mercadal S, Bdones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008; 19(5):958-963.
  • 8Reimer P, Rdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1 ): 106-113.
  • 9d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stam-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093-3099.
  • 10Rodriguez J, Conde E, Gutirrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18(4): 652-657.

共引文献31

同被引文献32

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部